Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Official Title

A Phase I/II, Multicentre, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies

Summary:

The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumour activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumours for whom no further effective standard treatment is available.

Trial Description

Primary Outcome:

  • Incidence of dose limiting toxicities (DLTs)
  • Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Secondary Outcome:
  • Overall Response Rate (ORR)
  • Duration of overall response (DOR)
  • Progression-free survival (PFS)
  • Best Overall Response (BOR)
  • Peak Plasma Concentration (Cmax) of MAK683
  • Area Under the Plasma Concentration (AUC) Time Curve of MAK683
  • Half-Life of MAK683
  • H3K27 tri methylation level in PBMC
The purpose phase I of this trial is to characterize safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683. The purpose of the phase II of this trial will be to evaluate the anti-tumour activity of MAK683.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society